Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
University of Michigan Rogel Cancer Center
10 participants
Aug 25, 2023
INTERVENTIONAL
Conditions
Summary
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.
Eligibility
Inclusion Criteria6
- Adult 18 years or older
- Referred for HSCT evaluation
- Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)
- Able to ambulate unassisted
- Ability to understand and the willingness to sign a written informed consent
- Ability to use Polar Flow heart rate application
Exclusion Criteria9
- Severe anemia (hemoglobin \<7 gm/dl)
- Untreated high-risk coronary artery disease (left main, triple vessel disease)
- Severe aortic stenosis
- Recent fracture as assessed via self-report
- Gross balance deficits
- Severe pain with basic movement
- Unable to ambulate unassisted or exercise
- NYHA class IV heart failure
- Adults unable to give consent, pregnant women, and prisoners are excluded from this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05945121